CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 9,057 enrolled
Drug / intervention
Not specified
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05227261
NCT05227261N/ACompleted

Assessment of a Novel Blood Test in Early Detection of the Five Common Cancers Based on the Investigation of the Circulating Tumour DNA

Gene Solutions·observational·Posted Feb 7, 2022·Updated Feb 18, 2025

In Brief

An observational study for Cancer, Lung and 6 related conditions. Completed, enrolled 9,057 participants across 1 site.

Detailed Summary

This is a multi-centre, prospective cohort study, aiming to evaluate a blood test in early detection of the four common cancers, based on the investigation of the circulating tumour DNA (ctDNA). Primary objective: To evaluate the performance characteristics of the blood ctDNA test in early detecting cancers. Secondary objectives: * To evaluate the performance characteristics of the test in determining the origin of tumour, as compared to the findings of the imaging diagnostic tests. * To determine the risk of cancers development in the high-risk population, as compared to that in the moderate-risk group.

Study Details

Timeline

N/ACompletedFinished
20222023202420252026
First PostedFeb 7, 2022
Enrollment StartApr 10, 2022
Primary CompletionApr 10, 2023
Study CompletionApr 10, 2024
TodayJul 2, 2026
Enrollment to primary: 1 yearPosted 4.4 years ago